SCHEMBL8239273

SCHEMBL8239273

CC(C)(C)OC(=O)N1CCN(C(=O)c2ncn(C3CCCN(C(=O)OCc4ccccc4)C3)c2-c2ccccc2)[C@H](Cc2ccccc2)C1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.49
ABHD6 Q9BV23 1/20 0.43
DAGLA Q9Y4D2 1/20 0.43
PRMT5 O14744 3/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
EGFR P00533 1/20 0.39
SRC P12931 1/20 0.39
HPGDS O60760 1/20 0.39
MAPT P10636 1/20 0.38
DPP4 P27487 1/20 0.38
BCL9 O00512 2/20 0.38
CTNNB1 P35222 2/20 0.38
JAK2 O60674 2/20 0.37
JAK1 P23458 2/20 0.37
TYK2 P29597 2/20 0.37
JAK3 P52333 2/20 0.37
USP30 Q70CQ3 1/20 0.37
NR1H2 P55055 2/20 0.37
NR1H3 Q13133 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8235955 0.92 ABHD6 (0.44) PARP1ABHD6DAGLAEGFRSRC
SCHEMBL3493565 0.92 PARP1 (0.40) PARP1JAK2JAK1TYK2JAK3
SCHEMBL8230171 0.90 ABHD6 (0.45) PARP1ABHD6DAGLAPRMT5EGFR
SCHEMBL13705167 0.90 ABHD6 (0.47) PARP1ABHD6DAGLAEGFRSRC
SCHEMBL8239198 0.89 NR1H2 (0.44) PARP1ABHD6DAGLAPRMT5EGFR
SCHEMBL8237252 0.88 ABHD6 (0.46) PARP1ABHD6DAGLAEGFRSRC
SCHEMBL13341129 0.88 ABHD6 (0.43) PARP1ABHD6DAGLAPRMT5EGFR
SCHEMBL13341101 0.88 ABHD6 (0.45) PARP1ABHD6DAGLAEGFRSRC
SCHEMBL8235756 0.87 ABHD6 (0.45) PARP1ABHD6DAGLAEGFRSRC
SCHEMBL8240230 0.87 ABHD6 (0.43) PARP1ABHD6DAGLAPRMT5EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100121048-A1 Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-05-13 US disclosed
WO-2007094513-A2 CYCLIC AMINE COMPOUND AND USE THEREOF FOR THE PROPHYLAXIS OR TREATMENT OF HYPERTENSION TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-08-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100121048-A1 Cyclic Amine Compound and Use Thereof for the Prophylaxis or Treatment of Hypertension REN, AGTR1, AGTR2 PARP1 2353/4885ABHD6 2780/4885DAGLA 4388/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.